Deborah A. f MD Kaseb Ahmed Omar g MD Cohen Lorenzo a PhD Bruera Eduardo a MD 9 2017 15 15 9 9 1111 1111 1120 1120 10.6004/jnccn.2017.0149 Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens
Search Results
- Sep 2017
Neel K. Gupta and Charalambos Andreadis
adverse events were neutropenia (≈33%) and infusion-related reactions (≈20%). The study 16 showed that obinutuzumab/chlorambucil induced deeper and longer remissions than rituximab/chlorambucil, and the FDA subsequently approved the combination of
Chest Radiography in the Initial Evaluation of Adult Patients With Febrile Neutropenia Patients Undergoing HSCT Yolin-Raley Deborah S. a PA-C Dagogo-Jack Ibiayi b MD Niell Heidi B. a PA-C Soiffer Robert J. a MD Antin Joseph H
- Feb 2015
Harold J. Burstein
. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no
Support Tool on Colony-Stimulating Factor Use and Chemotherapy-Induced Febrile Neutropenia Among Patients With Breast Cancer Agiro Abiy a PhD DeVries Andrea a PhD Malin Jennifer b MD, PhD Fisch Michael J. c MD, MPH 2 2018 16
- Feb 2018
: Immunotherapy for Colorectal Carcinoma Oh David Y. MD, PhD Venook Alan P. MD Fong Lawrence MD 8 2015 13 13 8 8 970 970 978 978 0130970 10.6004/jnccn.2015.0117 Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving
- Aug 2015
.6004/jnccn.2018.7053 A Study of Novel Febrile Neutropenia Risk Factors Related to Bone Marrow or Immune Suppression, Barrier Function, and Bacterial Flora Family Leila a PhD Li Yanli b PhD Chen Lie Hong c DPH Page John H. d MD, ScD
- Oct 2018
Marc Fishman, William Shimp, James Krook, Akhil Kumar and William J.M. Hrushesky
alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We
cytopenia(s),” “or increased marrow blasts” was added. Following “Clinically relevant thrombocytopenia or neutropenia,” “or increased marrow blasts” was added. “No response” was changed to “Disease progression/no response.” Footnote “bb” was added
Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead and Rashmi Kumar
to toxicity, 6 patients experienced nonhematologic grade 3/4 adverse events (20%), including muscle weakness, sepsis, and pneumonia; neutropenia and thrombocytopenia were seen in 2 patients (10%). 14 Based on data from the 3 phase II studies, 8 , 10
